Prosecution Insights
Last updated: April 19, 2026
Application No. 18/209,437

PYRROLINONE COMPOUND AND METHOD FOR PREPARING THE SAME

Non-Final OA §102§103§112
Filed
Jun 13, 2023
Examiner
WARD, PAUL V
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Wuhan Jianmin Dapeng Pharmaceutical Co. Ltd.
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
72%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allow Rate
1391 granted / 1672 resolved
+23.2% vs TC avg
Minimal -11% lift
Without
With
+-11.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
36 currently pending
Career history
1708
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
19.1%
-20.9% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
43.7%
+3.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1672 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION STATUS OF THE CLAIMS: Claims 1-22 are pending in this application. Election/Restrictions Applicant’s election of species in the reply filed on November 13, 2025 is acknowledged. This election was for search purposes only, and thus, all claims were examined. Claim Rejections - 35 USC § 112, 2nd paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 5-22 (including claims dependent thereon) is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being incomplete for omitting essential steps in claim 5. See MPEP § 2172.01. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3 are rejected under 35 U.S.C. 102 as being anticipated by Sun et al. (CN106674075). This reference discloses compounds of Applicant’s formula 1 on page 5. (See Abstract and entire document). These compounds read on the instant claim. Since this reference teaches the exact compounds, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102. Claims 1-2 are rejected under 35 U.S.C. 102 as being anticipated by Lombardi et al. (Org. Biomol. Chem.’2017). This reference discloses compounds of Applicant’s formula 1 on pages 8218 (Fig. 1), 8219 (Schemes 2-3 and Table 1), page 8220 (schemes 3-4) and page 8221 (scheme 5). (See Abstract and entire document). These compounds read on the instant claim. Since this reference teaches the exact compounds, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102. Claims 1-2 are rejected under 35 U.S.C. 102 as being anticipated by CAS Registry Number 771-82-2. Claims 1-2 are rejected under 35 U.S.C. 102 as being anticipated by CAS Registry Number 100383-27-5. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sun et al. (CN106674075). Applicants claim pyrrolinone compounds of the following formula 1: PNG media_image1.png 142 148 media_image1.png Greyscale wherein all the variables are defined in the claim as the following: PNG media_image2.png 164 618 media_image2.png Greyscale . Sun discloses a generic group pyrrolinone compounds of formula I, intermediates and Boc. Applicant claims differ from the reference by reciting specific species and a more limited genus than the reference (i.e., replacing R1, R2 and R3 with various substituents such as alkyls, phenyl, H, and alkoxy and alkylthio). It would have been obvious to one having ordinary skill in the art at the time of the invention to replace various substituents of formula I or add various substituents to formula I as taught by the reference, because it is generally known to a person skilled in the art that it would easily obtain other pyrrolinone compounds having through the substitution or changing of substituents. Additionally, Boc is a common protecting group used in synthetic chemistry. One of ordinary skill in the art would have been motivated to select the claimed compounds replacing R1, R2 and R3 with various substituents such as alkyls, phenyl, H, and alkoxy and alkylthio since such compounds would have been suggested by the reference as a whole. Further, a prior art disclosed genus of useful compounds is sufficient to render prima facie obvious a species falling within a genus. Thus, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Since Applicant’s claims are prima facie obvious in view of the teachings of Sun, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Claims 1-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wu Ronggui et al. (CN110092739). Applicants claim pyrrolinone compounds of the following formula 1: PNG media_image1.png 142 148 media_image1.png Greyscale wherein R1 is benzyloxy or phenyl and the other variables are defined in the claim. Wu Ronggui discloses a generic group pyrrolinone compounds of formula I, intermediates and Boc. Applicant claims differ from the reference by reciting specific species and a more limited genus. It would have been obvious to one having ordinary skill in the art at the time of the invention to replace various substituents of formula I or add various substituents to formula I as taught by the reference, because it is generally known to a person skilled in the art that it would easily obtain other pyrrolinone compounds having through the substitution or changing of substituents. Additionally, Boc is a common group used in synthetic chemistry. One of ordinary skill in the art would have been motivated to select the claimed compounds with various substituents since such compounds would have been suggested by the reference as a whole. Further, a prior art disclosed genus of useful compounds is sufficient to render prima facie obvious a species falling within a genus. Thus, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Since Applicant’s claims are prima facie obvious in view of the teachings of Wu Ronggui, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Claims 1-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thennati et al. (WO03057131). Applicants claim pyrrolinone compounds of the following formula 1: PNG media_image1.png 142 148 media_image1.png Greyscale wherein R1 is benzyloxy or phenyl and the other variables are defined in the claim. Thennati discloses a generic group pyrrolinone compounds of formula I, intermediates and Boc. Applicant claims differ from the reference by reciting specific species and a more limited genus than the reference. It would have been obvious to one having ordinary skill in the art at the time of the invention to replace various substituents of formula I or add various substituents to formula I as taught by the reference, because it is generally known to a person skilled in the art that it would easily obtain other pyrrolinone compounds having through the substitution or changing of substituents. Additionally, Boc is a common group used in synthetic chemistry. One of ordinary skill in the art would have been motivated to select the claimed compounds replacing R1, R2 and R3 with various substituents since such compounds would have been suggested by the reference as a whole. Further, a prior art disclosed genus of useful compounds is sufficient to render prima facie obvious a species falling within a genus. Thus, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Since Applicant’s claims are prima facie obvious in view of the teachings of Thennati, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Claims 5-12, 13-17 and 18-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jacobi et al. (J. Org. Chem.’2000). Applicants claim a method for preparing pyrrolinone compounds comprising: PNG media_image3.png 121 397 media_image3.png Greyscale Wherein all the variables are defined in the claim. Jacobi discloses for preparing pyrrolinone compounds comprising Applicant’s method and includes the solvents, acid-base substances and reaction conditions. (See pages 8479-84810. Applicant claims differ from the reference by reciting specific species and a more limited genus than the reference by using different substituents. It would have been obvious to one having ordinary skill in the art at the time of the invention to replace various substituents of formula I or add various substituents to formula I as taught by the reference, because it is generally known to a person skilled in the art that it would easily obtain other pyrrolinone compounds having through the substitution or changing of substituents. Additionally, Boc is a common group used in synthetic chemistry. One of ordinary skill in the art would have been motivated to select the methods and claimed compounds various substituents since such compounds and methods would have been suggested by the reference as a whole. Thus, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Since Applicant’s claims are prima facie obvious in view of the teachings of Jacobi, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Conclusion Claims 1-22 are pending. Claims 1-22 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL V WARD/ Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jun 13, 2023
Application Filed
Mar 07, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599666
PHOTOLYTIC COMPOUNDS AND TRIPLET-TRIPLET ANNIHILATION MEDIATED PHOTOLYSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12600705
HEAT SHOCK PROTEIN MODULATORS AND ANTI-HUNTINGTON DISEASE THERAPEUTIC AGENTS
2y 5m to grant Granted Apr 14, 2026
Patent 12600703
METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES
2y 5m to grant Granted Apr 14, 2026
Patent 12600700
IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY
2y 5m to grant Granted Apr 14, 2026
Patent 12599606
THERAPIES WITH 3RD GENERATION EGFR TYROSINE KINASE INHIBITORS
2y 5m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
72%
With Interview (-11.0%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 1672 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month